Results 221 to 230 of about 17,763 (261)
Some of the next articles are maybe not open access.
The Lancet, 2003
The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are rapidly fungicidal against most Candida spp and fungistatic against Aspergillus spp.
openaire +3 more sources
The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are rapidly fungicidal against most Candida spp and fungistatic against Aspergillus spp.
openaire +3 more sources
Tetrahedron Letters, 1992
Abstract Sodium cyanoborohydride in trifluoroacetic acid selectively reduced the C5-orn and C4-htyr carbinols to methylene groups in echinocandin lipopeptides. The selective reduction of either hydroxyl is also described. The first conversion of echinocandin B to echinocandin C was accomplished.
James M. Balkovec, Regina M. Black
openaire +1 more source
Abstract Sodium cyanoborohydride in trifluoroacetic acid selectively reduced the C5-orn and C4-htyr carbinols to methylene groups in echinocandin lipopeptides. The selective reduction of either hydroxyl is also described. The first conversion of echinocandin B to echinocandin C was accomplished.
James M. Balkovec, Regina M. Black
openaire +1 more source
Pharmacokinetics/pharmacodynamics of echinocandins
European Journal of Clinical Microbiology & Infectious Diseases, 2004The novel class of echinocandins represents a milestone in antifungal drug research that has further expanded our therapeutic options. The favorable pharmacokinetic profile of the echinocandins has been elucidated in animal and human studies. The echinocandins are targeted for once-daily dosing and are not metabolized through the cytochrome P450 enzyme
openaire +2 more sources
Echinocandins: The Expanding Antifungal Armamentarium
Clinical Infectious Diseases, 2015The echinocandins are large lipopeptide molecules that, since their discovery approximately 41 years ago, have emerged as important additions to the expanding armamentarium against invasive fungal diseases. Echinocandins exert in vitro and in vivo fungicidal action against most Candida species and fungistatic action against Aspergillus species. However,
Daniel, Aguilar-Zapata +2 more
exaly +3 more sources
Caspofungin: An echinocandin antifungal agent
Clinical Therapeutics, 2002The mainstays of treatment for nosocomial fungal infections have been amphotericin B and azole derivatives. Caspofungin acetate is a new echinocandin antifungal agent with a mechanism of action that targets a structural component of the fungal cell wall.This article describes the pharmacologic properties and potential clinical usefulness of caspofungin.
Elizabeth A, Stone +2 more
openaire +2 more sources
Anidulafungin: an echinocandin antifungal
Expert Opinion on Investigational Drugs, 2004Anidulafungin (LY-303366, V-echinocandin trade mark, Vicuron Pharmaceuticals, Inc.) is a new echinocandin antifungal agent with broad spectrum activity against Candida and Aspergillus spp. Anidulafungin exhibits low toxicity, concentration-dependent fungicidal activity for Candida, and a prolonged post antifungal effect (> 12h).
openaire +2 more sources
Micafungin: A New Echinocandin Antifungal
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007The echinocandins represent the newest class of antifungals to combat infections caused by Candida sp. Micafungin is an echinocandin recently approved by the United States Food and Drug Administration. It is indicated in adults for esophageal candidiasis and prophylaxis against candidal infections in hematopoietic stem cell transplant recipients ...
Jomy M, Joseph +2 more
openaire +2 more sources
Expert Opinion on Therapeutic Patents, 2002
Echinocandins and echinocandin-like compounds are non-competitive inhibitors of the synthesis of 1,3-β-D-glucan, a major and essential component in the wall of many important fungal pathogens. Since this polysaccharide is not present in mammalian cells the glucan synthase became an attractive target for the development of new antifungal agents.
openaire +1 more source
Echinocandins and echinocandin-like compounds are non-competitive inhibitors of the synthesis of 1,3-β-D-glucan, a major and essential component in the wall of many important fungal pathogens. Since this polysaccharide is not present in mammalian cells the glucan synthase became an attractive target for the development of new antifungal agents.
openaire +1 more source
Clinical efficacy of echinocandin antifungals
Current Opinion in Infectious Diseases, 2001The prevalence of fungal infections has increased significantly over the past few decades. Candida and Aspergillus spp. are the most common fungal pathogens due to recent changes in medical technology. Amphotericin B continues to be the treatment of choice in many severe disseminated mycosis cases, but problems with toxicity, resistance and non ...
openaire +2 more sources
Echinocandin antifungals: review and update
Expert Review of Anti-infective Therapy, 2006The echinocandins are a new and unique class of antifungal agents that act on the fungal cell wall by way of noncompetitive inhibition of the synthesis of 1,3-beta-glucans. All agents of this class are of parenteral formulation, with no oral preparations available.
openaire +2 more sources